LAVA Therapeutics Q2 EPS $(0.48) Misses $(0.47) Estimate, Sales $5.14M Beat $830.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
LAVA Therapeutics reported Q2 losses of $(0.48) per share, missing the analyst consensus estimate of $(0.47) by 2.13%. This is a 54.84% decrease from the same period last year. However, the company's quarterly sales of $5.14 million beat the analyst consensus estimate of $830.00 thousand by 519.28%, a 998.29% increase from last year.
August 22, 2023 | 11:17 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
LAVA Therapeutics reported lower than expected Q2 earnings but significantly higher sales.
While LAVA Therapeutics missed earnings estimates, the significant beat on sales could balance out the impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100